8-K current report · filed Sep 30, 2026

Celcuity Inc. (CELC) 8-K Current Report: September 30, 2026

Item 8.01Item EX-99.1Item 7.01CELC overview

Short answer

Celcuity Inc. (CELC) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). REVTORPYK (gedatolisib) now commercially available in the U.S. for eligible breast cancer patients.

Celcuity Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • REVTORPYK (gedatolisib) now commercially available in the U.S. for eligible breast cancer patients
  • Indication: HR+, HER2-, locally advanced or metastatic disease after endocrine-therapy progression
  • Eligibility excludes patients with detected PIK3CA mutations
  • Commercial launch creates potential revenue opportunity and validates gedatolisib’s regulatory pathway

Item 8.01 · Other Events

  • REVTORPYK commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients
  • Indicated after progression following at least one metastatic-setting endocrine therapy line
  • Eligibility excludes patients with detected PIK3CA mutations
  • Commercial launch expands potential revenue opportunity in the U.S. oncology market

Item EX-99.1 · Exhibit EX-99.1

  • REVTORPYK became commercially available in the U.S. on September 30, 2026, initiating Celcuity’s first product launch
  • FDA-approved for HR+/HER2- advanced breast cancer without detected PIK3CA mutation after at least one metastatic endocrine-therapy line
  • Triplet reduced progression or death risk 76%; doublet reduced risk 67% versus fulvestrant in VIKTORIA-1’s PIK3CA wild-type cohort
  • REVTORPYK Support Services launched with insurance navigation, copay assistance, and patient assistance programs
  • Supplemental application submitted in August for PIK3CA-mutated disease, potentially expanding the eligible treatment population

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Celcuity Inc. 8-K filings

Get the next CELC 8-K as it lands

Follow CELC for push alerts, or ask the research agent what this filing means.